T he product package insert remains the cornerstone for drug prescribing. Over the last 2 decades, there have been significant increases in the length and complexity of the product information insert, making it difficult to locate specific information in a timely manner. For some drugs, the package insert changes several times over the market-life. Many of these changes relate to the safety profile of a drug (eg, adverse drug reactions, interactions, use in pregnancy information). It is not surprising that an increased emphasis on post-marketing surveillance has also resulted in successive updates in packet inserts.
For the first time in 25 years, the FDA recently announced a major revision to the format of the package insert of prescription drugs. These changes were designed to provide health professionals with clear and concise prescribing information and to "enhance the safe and effective use of prescription drugs and reduce the number of adverse reactions resulting from medication errors due to misunderstood or incorrectly applied drug information." 1 The ruling, effective June 30 th of this year, requires all newly approved drugs, and those approved within the last 5 years, to meet the revised formatting guidelines. 2 All health professionals should be aware of the planned changes. The new format should provide the most important information "up-front." In addition, it is hoped that the newer format will allow prescription information to be more accessible for use in electronic prescribing tools and in electronic information resources. Specific changes include a new section entitled Highlights, which will be approximately half a page in length and will summarize the most important prescribing information about the benefits and risks of the drug, including Boxed Warnings, Indications and Usage, and Dosage and Administration. All substantial changes made to the package insert within the last year will also be listed to familiarize prescribers and health professionals with the most recent changes. In addition, a Table of Contents will be provided for easy reference to details about specific safety and efficacy information. One of the more practical changes proposed is the addition of the initial productapproval date, which allows the reader to easily determine how long a product has been on the market. In an effort to promote further patient safety and encourage the reporting of adverse drug reactions, a toll-free number and Internet reporting information will be provided. One of the most significant changes involves the addition of a new Patient Counseling Information section, designed to assist in the counseling of patients regarding the most important uses and limitations of their medications.
Health professionals should be aware that the new prescription information format will be integrated into the electronic resources of the FDA, including a new online information product, entitled Daily Med (http://dailymed. nlm.nih.gov).
There is no doubt that these planned changes were overdue and that they will impact the delivery of information to the patient. Hospital Pharmacy is interested in hearing about any new programs or health care initiatives designed to use the new features of the package insert. Please send your information to hospitalpharmacy@ drugfacts.com.
